20:14:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-21 15-10 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017


ListaFirst North Stockholm
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-11-10 08:45:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the CE-Marking of the IndiTreat® Image Uploader, a software application that is critical to enable IndiTreat® testing at hospitals. The company announced on October 26th 2023 that it would focus all resources on making IndiTreat® testing available at hospitals worldwide by accelerating the development of an automated IVD system.

IndiTreat® Image Uploader: linking the images from each hospital to 2cureX AI algorithms

The decentralized testing model implies that hospitals will conduct the whole IndiTreat® process in-house, using the automated IVD system (instruments, reagents, consumables, and software) provided by 2cureX. Nevertheless, the image analysis and report generation steps will be performed at 2cureX central servers, using the company’s proprietary software and AI algorithms. In this way, customers will benefit from an ever-growing global database to compare a patient’s results with others in similar circumstances.

It is, therefore, crucial that the tumoroid images captured at the hospital can be transferred to the central server in a smooth, fast, safe and secure way.

The IndiTreat® Image Uploader is a software application designed to facilitate the secure transfer of IndiTreat® screening image files from a local computer to a centralized server for downstream data processing and analysis. The software controls users’ rights and ensures data integrity and authenticity, streamlining the upload process and enhancing the overall productivity of IndiTreat® operations at hospitals labs.

“We are very satisfied with this milestone”, says Jacob Thastrup, Director of Product Development. “The development and launch of an automated IVD system – a project we named ZENITH – involves developing and CE-marking not only the instrument, but also its associated reagents, consumables and software. We are developing and CE-marking more than ten products in parallel, so each one we complete is a very important achievement”.

The IndiTreat® Image Uploader has been CE-Marked in compliance with Regulation (EU) 2017/746, also known as IVD-R, and is the third 2cureX product under this regulation, after the IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container launched on August 30th 2023.

Decentralization of IndiTreat® testing to trigger mainstream use

IndiTreat® is currently offered as a service, out of a centralized lab location – a model used by all suppliers of Functional Drug Sensitivity Tests – but experience shows that this model is not suitable for mainstream use as it disrupts the hospital workflows and requires too complex sample logistics. By enabling in-house testing at customer’s labs, 2cureX aims at leveraging its first mover advantage and building a global leader position in an emerging segment that is expected to become a multi- billion USD per year market.

“Our teams are doing an excellent job in reaching the milestones of the ZENITH project. We are determined to be the first company to launch an automated IVD System for hospital in-house Functional Drug Sensitivity Testing”, says Fernando Andreu, CEO of 2cureX.